It is also useful in pain control for neuropathic pain, chronic pain and palliative care — "comfort care" — for those with intractable pain from treatment resistant, untreatable, and incurable diseases. When combined with opioids it increases the level of analgesia (pain relief) obtained.[9] Several mechanisms are thought to contribute to this effect. The closely related drugs atropine and hyoscine and other members of the anticholinergic drug group like cyclobenzaprine, trihexyphenidyl, and orphenadrine are also used for this purpose.[10] When hyoscyamine is used along with opioids or other anti-peristaltic agents, measures to prevent constipation are especially important given the risk of paralytic ileus.[11]
Adverse effects
Side effects include dry mouth and throat, increased appetite leading to weight gain, eye pain, blurred vision, restlessness, dizziness, arrhythmia, flushing, and faintness.[6] An overdose will cause headache, nausea, vomiting, and central nervous system symptoms including disorientation, hallucinations, euphoria, sexual arousal, short-term memory loss, and possible coma in extreme cases. The euphoric and sexual effects are stronger than those of atropine but weaker than those of hyoscine, as well as dicycloverine, orphenadrine, cyclobenzaprine, trihexyphenidyl, and ethanolamine antihistamines like phenyltoloxamine.[12][13]
Hyoscyamine has been described as a selective muscarinic acetylcholine M2 receptorantagonist without significant effects at the other muscarinic acetylcholine receptors.[16][17] This is in contrast to related antimuscarinics like atropine and scopolamine, which are non-selective antagonists of all five muscarinic acetylcholine receptors.[16][17] Antagonism of both the muscarinic acetylcholine M1 receptor and M2 receptor has been implicated as having negative effects on memory and cognition.[17] Hyoscyamine has been described as having deliriant effects similarly to scopolamine, atropine, and other antimuscarinics.[16] However, other sources have reported that hyoscyamine potently antagonizes all five muscarinic acetylcholine receptor subtypes.[18]
A putrescine oxidase (EC 1.4.3.10) that specifically recognizes methylated putrescine catalyzes the deamination of this compound to 4-methylaminobutanal which then undergoes a spontaneous ring formation to N-methylpyrrolium cation. In the next step, the pyrrolium cation condenses with acetoacetic acid yielding hygrine. No enzymatic activity could be demonstrated that catalyzes this reaction. Hygrine further rearranges to tropinone.[19]
Ingredients of a "Clap Mixture" (medical formulation), putatively hyoscyamine-containing, "Clap" being a colloquial synonym for "the sexually transmitted infection, gonorrhea". Interpretation of the label by Wikipedia editors deduce the "Extr. H..." (label obscured, at end of the first text line under the title) to refer to the article title subject, hysoscyamine, here putatively as a natural product extracted from an unspecified plant. Other indicated ingredients are interpreted to be: "Sod. Cit.", sodium citrate; "Sod. Bic., sodium bicarbonate; "Chlorof.", chloroform; "Aq.", aqueous, hence, the deduction is that this is an extract of hyoscyamine formulated for treatment of "the clap," also containing sodium citrate and sodium bicarbonate, in a solution/mixture of chloroform and water.
↑ Kang M, Galuska MA, Ghassemzadeh S (2022). "Benzodiazepine Toxicity". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID29489152. Archived from the original on 20 August 2022.
↑ Edwards Pharmaceuticals, Inc., Belcher Pharmaceuticals, Inc. (May 2010). "DailyMed". U.S. National Library of Medicine. Retrieved 13 January 2013.
1 2 Kapoor AK, Raju SM (2013). "2.3 Cholinergic Drugs—Antagonists (Inhibition) of Cholinergic Receptors". Illustrated Medical Pharmacology. New Delhi, India: Jaypee Brothers Medical Publishers. pp.127, 129–131, esp. 131. ISBN9789350906552. Retrieved 11 January 2014.[bettersourceneeded] Note, no actual content is available via the current web link.
1 2 3 Lakstygal AM, Kolesnikova TO, Khatsko SL, Zabegalov KN, Volgin AD, Demin KA, etal. (May 2019). "DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens". ACS Chem Neurosci. 10 (5): 2144–2159. doi:10.1021/acschemneuro.8b00615. PMID30566832.
1 2 3 Shim KH, Kang MJ, Sharma N, An SS (September 2022). "Beauty of the Beast: Anticholinergic Tropane Alkaloids in Therapeutics". Nat Prod Bioprospect. 12 (1) 33. doi:10.1007/s13659-022-00357-w. PMC9478010. PMID36109439. Antagonism at M1 and M2 receptors have negative impact on memory and cognition [60]. [...] Atropine and scopolamine are non-selective competitive antagonist of muscarinic receptors. Atropine has the highest affinity for subtype M1, followed by M2 and M3 and weak affinity for M4 and M5 [71]. On the other hand, scopolamine has strong affinity for M1-M4 compared to M5 [72] while hyoscyamine binds to M2 only [73].
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.